Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea

다국어 초록 (Multilingual Abstract)

This study evaluated the toxicity profiles of temozolomide in the treatment of malignantglioma as either concurrent or adjuvant chemotherapy. We retrospectively reviewed themedical records of 300 malignant glioma patients treated with temozolomide in twomedical institutions in Korea between 2004 and 2010. Two hundred nine patientsexperienced a total of 618 toxicities during temozolomide therapy. A total of 84.8% of the618 toxicities were Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or 2,while 15.2% were grade 3 or 4. Among the hematologic toxicities, thrombocytopenia(13.7%), anemia (11.0%), and AST/ALT increases (7.0%) were common. Among the nonhematologictoxicities, nausea (44.3%), vomiting (37.0%), and anorexia (14.3%) were thethree most common toxicities. There was no mortality due to temozolomide. Althoughtemozolomide showed many types of toxicities, the majority of the toxicities were tolerableand of lower grade. Gastrointestinal troubles are the most common toxicities in Koreanpatients treated with temozolomide.

참고문헌 (Reference)

1 송경호, "항암치료 중 구역과 구토의 처치" 대한내과학회 82 (82): 532-536, 2012

2 Kuchinski AM, "Treatment-related fatigue and exercise in patients with cancer : a systematic review" 18 : 174-180, 2009

3 Young KE, "The prevalence and moderators of fatigue in people who have been successfully treated for cancer" 60 : 29-38, 2006

4 Poirier P, "The impact of fatigue on role functioning during radiation therapy" 38 : 457-465, 2011

5 Athanassiou H, "Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme" 23 : 2372-2377, 2005

6 Walker MD, "Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery" 303 : 1323-1329, 1980

7 Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma" 352 : 987-996, 2005

8 Stupp R, "Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide" 20 : 1375-1382, 2002

9 Kesari S, "Phase II study of protracted daily temozolomide for low-grade gliomas in adults" 15 : 330-337, 2009

10 Kim SG, "Managements of chemotherapy induced nausea and vomiting" 8 : 23-29, 2012

11 Zwinkels H, "Management of temozolomide toxicity by nurse practitioners in neuro-oncology" 36 : 225-231, 2009

12 Vadhan-Raj S, "Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents" 46 : S26-S32, 2009

13 Khasraw M, "Long-term use of temozolomide: could you use temozolomide safely for life in gliomas?" 16 : 854-855, 2009

14 Jordan K, "International antiemetic guidelines on chemotherapy induced nausea and vomiting(CINV) : content and implementation in daily routine practice" 722 : 197-202, 2014

15 Stone P, "Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy" 22 : 1007-1015, 2001

16 Lee H, "Effects of a nurse-led cognitive-behavior therapy on fatigue and quality of life of patients with breast cancer undergoing radiotherapy: an exploratory study" 34 : E22-E30, 2011

17 Middleton J, "Effectively managing chemotherapy-induced nausea and vomiting" 20 : S7-S15, 2011

18 Zeuner A, "Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor" 67 : 4767-4773, 2007

19 Hawkins R, "Chemotherapy-induced nausea and vomiting : challenges and opportunities for improved patient outcomes" 13 : 54-64, 2009

20 National Cancer Institute, "CTCAE v3.0"

21 Panet-Raymond V, "Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme : a safety and efficacy analysis" 73 : 473-478, 2009